1. Pink Sheet
  2. >>Agency Leadership

Pfizer Reorganizes Internally As It Moves Closer To Decision On Splitting Business

 
• By Wendy Diller

Beginning in January 2014, Pfizer is realigning its commercial operations into three organizations, in effect taking the next step on its multi-year deliberation over whether to split up its behemoth business.

Pfizer Inc. is reorganizing its commercial operations into three business segments, and has named top executives to run them, broadly in line with plans it has outlined in discussions over the past two years with Wall Street analysts.

As of Jan. 1, 2014 in much of the world, it is forming two businesses focusing on innovative products and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Agency Leadership

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.